Treatment of amyotrophic lateral sclerosis
The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
1. A compound selected from compounds of a formula
wherein R 1 and R 2 are independently selected from H, alkyl and arylalkyl moieties; salts; tautomers; or combinations thereof.
2. The compound of claim 1 wherein R 1 is alkyl, and R 2 is selected from H, methyl and benzyl moieties.
3. The compound of claim 1 wherein R 1 is selected from methyl and ethyl moieties, and R 2 is selected from H and benzyl moieties.
4. A method of modulating the activity of a mutant superoxide dismutase 1 in the treatment of amyotrophic lateral sclerosis (ALS), said method comprising:
providing a compound of claim 1 ; and
contacting said compound with a cellular medium expressing a mutant superoxide dismutase 1, said compound in an amount sufficient to affect protein aggregation within said cellular medium.
5. The method of claim 4 wherein R 1 is alkyl.
6. The method of claim 5 wherein said compound is in a fluid medium.
7. The method of claim 6 wherein a tautomer of said compound is present.